Company Filing History:
Years Active: 2008
Title: David Ferández Bleda: Innovator in Antitumor Compounds
Introduction
David Ferández Bleda is a notable inventor based in Barcelona, Spain. He has made significant contributions to the field of pharmaceuticals, particularly in the development of antitumor compounds. His innovative work has led to the creation of a patent that showcases his expertise and dedication to advancing medical science.
Latest Patents
David Ferández Bleda holds a patent for "Derivatives of variolin B." This invention provides antitumor compounds of formula (I), wherein R is an aromatic substituent. R can be hydrogen or a substituent when the dotted line is absent, or R is absent when the dotted line represents a bond to give a double bond between the nitrogen which bears R and the carbon which bears R. Additionally, R is an oxo group when the dotted line is absent or is a substituent when the dotted line represents a bond to give a double bond between the nitrogen bearing R and the carbon bearing R. R can also be hydrogen or a substituent, along with pharmaceutically acceptable salts thereof. This patent highlights his innovative approach to cancer treatment.
Career Highlights
David Ferández Bleda is associated with Pharma Mar, S.A., a company known for its focus on marine-derived pharmaceuticals. His work at Pharma Mar has allowed him to contribute to groundbreaking research and development in the pharmaceutical industry. His dedication to innovation is evident in his patent and ongoing research efforts.
Collaborations
David has collaborated with esteemed colleagues such as Mercedes Alvarez and José Luis Fernández Puentes. These collaborations have fostered a productive environment for innovation and have contributed to the advancement of their shared goals in pharmaceutical research.
Conclusion
David Ferández Bleda is a prominent figure in the field of pharmaceuticals, with a focus on developing antitumor compounds. His patent for derivatives of variolin B exemplifies his commitment to innovation and improving cancer treatment options. His contributions, along with his collaborations, continue to make a significant impact in the industry.